Ocular Therapeutix (OCUL) Preferred Dividend Payments (2013 - 2014)
Ocular Therapeutix's (OCUL) quarterly Preferred Dividend Payments came in at $5000.0 in Q2 2014, up 155.56% year-on-year from $1956.5 in Q2 2013, and down 16.67% quarter-over-quarter from $6000.0 in Q1 2014.
Ocular Therapeutix (OCUL) Preferred Dividend Payments (2013 - 2014) Analysis & Trends
Ocular Therapeutix's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $5000.0 for Q2 2014.
- On a quarterly basis, Preferred Dividend Payments rose 155.56% year-over-year to $5000.0 in Q2 2014; TTM through Dec 2014 was $11000.0, a N/A change from a year earlier, with the FY2014 full-year figure at $11000.0, down 59.26% from the prior year.
- Preferred Dividend Payments retreated to $5000.0 in Q2 2014 per OCUL's latest filing, from $6000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $49000.0 in Q4 2013 and bottomed at -$9000.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Ocular Therapeutix | 1.91 Bn | 1.91 Bn | 9.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 5,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Dec 31, 2013 | 49,000.00 |
| Sep 30, 2013 | -5,000.00 |
| Jun 30, 2013 | -9,000.00 |